Citation: | Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 8-14, 28. doi: 10.3969/j.issn.1674-7445.2021.01.002 |
[1] |
HALLIDAY N, WESTBROOK RH. Liver transplantation: post-transplant management[J]. Br J Hosp Med (Lond), 2017, 78(5):278-285. DOI: 10.12968/hmed.2017.78.5.278.
|
[2] |
SHAKED A, DESMARAIS MR, KOPETSKIE H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation[J]. Am J Transplant, 2019, 19(5):1397-1409. DOI: 10.1111/ajt.15205.
|
[3] |
JUCAUD V, SHAKED A, DESMARAIS M, et al. Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients[J]. Hepatology, 2019, 69(3):1273-1286. DOI: 10.1002/hep.30281.
|
[4] |
GUO T, LEI J, GAO J, et al. The hepatic protective effects of tacrolimus as a rinse solution in liver transplantation: a Meta-analysis[J]. Medicine (Baltimore), 2019, 98(21): e15809. DOI: 10.1097/MD.0000000000015809.
|
[5] |
RAYAR M, TRON C, LOCHER C, et al. Tacrolimus concentrations measured in excreted bile in liver transplant recipients: the STABILE study[J]. Clin Ther, 2018, 40(12):2088-2098. DOI: 10.1016/j.clinthera. 2018.10.015.
|
[6] |
SALIBA F, ROSTAING L, GUGENHEIM J, et al. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study[J]. Transplantation, 2016, 100(8):1705-1713. DOI: 10.1097/TP.0000000000001228.
|
[7] |
GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with Meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10):1260-1273. DOI: 10.1111/apt.15253.
|
[8] |
JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7):932-945. DOI: 10.1002/lt.25191.
|
[9] |
PERITO ER, MARTINEZ M, TURMELLE YP, et al. Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials[J]. Am J Transplant, 2019, 19(5):1545-1551. DOI: 10.1111/ajt.15255.
|
[10] |
CASTEDAL M, SKOGLUND C, AXELSON C, et al. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation[J]. Scand J Gastroenterol, 2018, 53(6):741-747. DOI: 10.1080/00365521.2018.1463390.
|
[11] |
KOO J, WANG HL. Acute, chronic, and humoral rejection: pathologic features under current immunosuppressive regimes[J]. Surg Pathol Clin, 2018, 11(2):431-452. DOI: 10.1016/j.path.2018.02.011.
|
[12] |
AIBARA N, OHYAMA K, HIDAKA M, et al. Immune complexome analysis of antigens in circulating immune complexes from patients with acute cellular rejection after living donor liver transplantation[J]. Transpl Immunol, 2018, 48:60-64. DOI: 10.1016/j.trim.2018.02.011.
|
[13] |
LO RC, CHAN KK, LEUNG CO, et al. Expression of hepatic progenitor cell markers in acute cellular rejection of liver allografts-an immunohistochemical study[J]. Clin Transplant, 2018, 32(3):e13203. DOI: 10.1111/ctr.13203.
|
[14] |
LEE M. Antibody-mediated rejection after liver transplant[J]. Gastroenterol Clin North Am, 2017, 46(2): 297-309. DOI: 10.1016/j.gtc.2017.01.005.
|
[15] |
RODRÍGUEZ-PERÁLVAREZ M, RICO-JURI JM, TSOCHATZIS E, et al. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal[J]. Transpl Int, 2016, 29(9):961-973. DOI: 10.1111/tri.12737.
|
[16] |
MCALISTER VC. Anti-donor immunoglobulin G subclass in liver transplantation[J]. Hepatobiliary Surg Nutr, 2019, 8(2):125-128. DOI: 10.21037/hbsn.2018.12.09.
|
[17] |
JADLOWIEC CC, TANER T. Liver transplantation: current status and challenges[J]. World J Gastroenterol, 2016, 22(18):4438-4445. DOI: 10.3748/wjg.v22.i18.4438.
|
[18] |
FENG S, BUCUVALAS JC, DEMETRIS AJ, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants[J]. Gastroenterology, 2018, 155(6):1838-1851. DOI: 10.1053/j.gastro.2018.08.023.
|
[19] |
BITAR C, OLIVIER K, LEE C, et al. Acute graft-vs-host disease following liver transplantation[J]. Cutis, 2019, 103(6):E8-E11.
|
[20] |
马明, 蒋文涛.肝移植术后移植物抗宿主病[J/CD].实用器官移植电子杂志, 2014, 2(4): 249-252. DOI: 10.3969/j.issn.2095-5332.2014.04.012.
MA M, JIANG WT. Graft versus host disease after liver transplantation[J/CD]. Prac J Organ Transplant(Electr Vers), 2014, (4): 249-252. DOI: 10.3969/j.issn.2095-5332.2014.04.012.
|